What is a key safety concern when combining daptomycin with statin therapy?

• A. Increased risk of myopathy and elevated CK.
• B. Severe hepatotoxicity.
• C. Severe anemia.
• D. Nephrotoxicity.

Answer: (A)

The main idea is that muscle toxicity is the key safety concern when daptomycin is used with a statin. Daptomycin can cause myopathy and increases in creatine kinase (CK), and statins can also cause myopathy and, in some cases, rhabdomyolysis—especially at higher doses or with interactions. Put together, the risk of muscle injury becomes higher because the toxic effects on muscle can add up from both drugs. That’s why the best answer is the increased risk of myopathy and CK elevation. In practice, clinicians monitor CK levels and muscle symptoms and may hold or adjust the statin during daptomycin therapy, particularly if CK rises or muscle symptoms occur. Severe hepatotoxicity, severe anemia, and nephrotoxicity are less directly tied to this drug interaction.